biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Looks like fuzzy is all in.

<< Previous

Bullboard Posts

Next >>

Comment by JDavenporton Dec 16, 2022 11:28am

105 Views

Post# 35175831

RE:RE:Looks like fuzzy is all in.

Hah! Biodexa will have control of xB3, but they've placed value only on existing xB3 deals, and on xB3 helping the Midatech legacy programs.

Otherwise, none of the players in this deal have expressed anything about the value of the xB3 platform.

I've explained why I think that is so.

Meanwhile, Bioasis and Midatech are burning to the ground and the deal gang are doing nothing to prevent it.

And you support them, pof, fuzzy, etc.

jd

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario